---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-193940"
form_type: "8-K/A"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:02:08.963183+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation

## Summary
- Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.
- Dr. Sullivan will receive current salary for 18 months and health coverage for up to 12 months.
- All unvested RSUs and stock options accelerated; option exercise period extended to December 31, 2030.
- One-year post-separation non-solicitation and mutual non-disparagement covenants apply.

## SEC filing metadata
- accession: 0001193125-26-193940
- form_type: 8-K/A
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/pyxs-20260206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-193940
- JSON: https://secwatch.observer/filing/0001193125-26-193940.json
- Plain text: https://secwatch.observer/filing/0001193125-26-193940.txt

## Key facts
- Executive change
  Lara Sullivan resigned as Director at Pyxis Oncology, Inc..
  - Action: resigned
  - Role: Director
  source text: Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm
- Executive change
  Lara Sullivan departed as Chief Executive Officer at Pyxis Oncology, Inc..
  - Action: separated
  - Role: Chief Executive Officer
  source text: On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000119312526193940/0001193125-26-193940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.